Johnson & Johnson (JNJ)vsTalkspace Inc (TALK)
JNJ
Johnson & Johnson
$254.66
+3.99%
HEALTHCARE · Cap: $613.02B
TALK
Talkspace Inc
$5.19
-0.19%
HEALTHCARE · Cap: $869.41M
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 40326% more annual revenue ($96.36B vs $238.37M). JNJ leads profitability with a 21.8% profit margin vs 0.5%. JNJ earns a higher WallStSmart Score of 57/100 (C).
JNJ
Buy57
out of 100
Grade: C
TALK
Hold41
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-87.1%
Fair Value
$136.12
Current Price
$254.66
$118.54 premium
Intrinsic value data unavailable for TALK.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 26 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 27.4%
Generating 1.5B in free cash flow
Earnings expanding 181.1% YoY
Safe zone — low bankruptcy risk
18.2% revenue growth
Areas to Watch
Moderate valuation
Expensive relative to growth rate
Earnings declined 52.9%
Smaller company, higher risk/reward
ROE of 1.0% — below average capital efficiency
0.5% margin — thin
Operating margin of 0.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.8% and operating margin at 27.4%.
Bull Case : TALK
The strongest argument for TALK centers on EPS Growth, Altman Z-Score, Revenue Growth. Revenue growth of 18.2% demonstrates continued momentum.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Bear Case : TALK
The primary concerns for TALK are Market Cap, Return on Equity, Profit Margin. Thin 0.5% margins leave little buffer for downturns.
Key Dynamics to Monitor
JNJ profiles as a mature stock while TALK is a growth play — different risk/reward profiles.
TALK carries more volatility with a beta of 1.07 — expect wider price swings.
TALK is growing revenue faster at 18.2% — sustainability is the question.
JNJ generates stronger free cash flow (1.5B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (57/100 vs 41/100), backed by strong 21.8% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Talkspace Inc
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
Talkspace Inc. is a virtual behavioral healthcare company. The company is headquartered in New York, New York.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?